Kabra Drugs Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
- Paid Up Capital ₹ 10.08 Cr
- Company Age 35 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.99 Cr
About Kabra Drugs
Kabra Drugs Limited (KDL) is a Public Limited Indian Non-Government Company incorporated in India on 22 August 1989 and has a history of 35 years and five months. Its registered office is in Indore, Madhya Pradesh, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524322.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 10.08 Cr.
The company has closed loans amounting to ₹1.99 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Kabra Drugs Limited India are Bangalore Kumar as CFO and Monika Gattani as Company Secretary. Nanjappan Aravind, Anand Anitha, Kuniamuthur Anand, and Two other members serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
L02423MP1989PLC005438
-
Company No.
005438
-
Stock Symbol
BSE : 524322
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
22 Aug 1989
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Listed
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Kabra Drugs?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nanjappan Aravind
|
Managing Director | 14-Aug-2024 | Current |
|
Bangalore Kumar
|
CFO | 29-Jan-2020 | Current |
|
Monika Gattani
|
Company Secretary | 14-Jul-2022 | Current |
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Anand Anitha
|
Director | 14-Jul-2022 | Current |
|
Kuniamuthur Anand
|
Director | 09-Jun-2022 | Current |
|
Bangalore Kumar
|
Whole-Time Director and Cfo | 29-Jan-2020 | Current |
|
Ananthkumar Shilpa
|
Director | 19-Feb-2020 | Current |
Financial Performance of Kabra Drugs.
Kabra Drugs Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kabra Drugs?
In 2023, Kabra Drugs had a public holding of 100.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Patchala Spintex Private LimitedMonika Gattani is a mutual person
-
Drushya Entertainment Broadcast Streams LimitedKuniamuthur Anand is a mutual person
-
Nexgen Animators Private Limited
Kuniamuthur Anand is a mutual person
Charges (Loans)
₹0
₹1.99 Cr
Charges Breakdown by Lending Institutions
- Religare Finvest Limited : 1.51 Cr
- Bank Of India : 0.48 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2014 | Religare Finvest Limited | ₹1.51 Cr | Satisfied |
| 13 Nov 2010 | Bank Of India | ₹4.80 M | Satisfied |
How Many Employees Work at Kabra Drugs?
Unlock and access historical data on people associated with Kabra Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kabra Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kabra Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
